As the global population ages and the incidence of chronic diseases rises, the demand for cutting-edge healthcare solutions remains unwavering. This persistent and growing need is set to establish a resilient and thriving market for biotech products.
Amid such heightened demand, three fundamentally sound biotech stocks, Vanda Pharmaceuticals Inc. (VNDA), Organogenesis Holdings Inc. (ORGO), and Exelixis, Inc. (EXEL) could be better buys than Bionano Genomics, Inc. (BNGO). Let us understand why.
